Post-approval studies (Phase 4)Not Yet RecruitingNCT07075250
What this trial is testing
Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)
Peking University People's Hospital 30